Via the analysis of the relationship between the mutations of the four “key drivers” of pancreatic cancer and risk score, we found that patients with higher risk score were enriched for KRAS mutations (P<0.001, Figure 7A) and TP53 mutations (P < 0.001, Figure 7B). The gene discussed is KRAS; the disease is pancreatic neoplasm.